Undisclosed nectin4 ADC / CSPC Pharma, NovaRock Biotherapeutics - LARVOL DELTA

A phase 1b study of SYS6002 in advanced solid tumors. (ASCO 2026) - P1 | "SYS6002 demonstrated a distinct safety profile from other Nectin-4 ADCs. Its promising efficacy in aUC patients, extending to those progressing on prior MMAE-based ADCs, supports further phase 3 trials."

Metastases • P1 data • Dry Eye Disease • Oncology • Ophthalmology • Solid Tumor • Steven-Johnson Syndrome • Urothelial Cancer • NECTIN4

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC). (ASCO-GU 2024) - "SYS6002 (CRB-701) is a next generation Nectin-4 ADC that makes use of third-generation conjugation technology designed to overcome dose-limiting toxicities observed with the commonly approved linker-payload system involved in agents like enfortumab vedotin (EV). SYS6002 (CRB-701) was well tolerated in escalation, and relative to EV demonstrates early signs of a differentiated safety and PK (longer half-life and lower free-MMAE) profile. Continued development of SYS6002 (CRB-701) as both a monotherapy and in combination are planned. Clinical trial information: SYS6002-001."

P1 data • Genito-urinary Cancer • Urothelial Cancer • NECTIN4